EFFECTS OF ANF PROHORMONE PEPTIDES IN CONSCIOUS PRIMATES

1. Recent studies suggest that amino-terminal peptides from the atrial natriuretic factor (ANF) prohormone are natriuretic. 2. The effects of pro ANF 31–67 and ANF 99–126 on renal function were studied in conscious non-human primates (Macaca fuscicularis). 3. Results show that pro ANF 31–67 and ANF 99–126 are diuretic and natriuretic and that when the two peptides are given in combination sodium excretion increases in an additive fashion. 4. These results indicate that multiple peptides from the ANF prohormone are natriuretic. Furthermore, these findings suggest that the combined action of these peptides causes the natriuresis that occurs after the release of endogenous atrial peptides.     

NATRIURETIC AND HYPOTENSIVE EFFECTS OF BRAIN NATRIURETIC PEPTIDE IN ANAESTHETIZED DOCA-SALT HYPERTENSIVE RATS

1. Both natriuretic and hypotensive effects of brain natriuretic peptide (BNP), a novel peptide identified in porcine brain, were investigated in anaesthetized DOCA-salt rats and control rats. 2. An intravenous injection of two different doses (0.5 and 5.0 nmol/kg) of BNP produced a rapid and marked natriuresis and hypotension in DOCA-salt rats. 3. In particular, significant differences of responsiveness were observed between DOCA-salt and control rats when administered the lower dose of BNP. 4. It was suggested that DOCA-salt rats might be relatively more susceptible to BNP.     

NATRIURETIC AND HYPOTENSIVE EFFECTS OF α-HUMAN ATRIAL NATRIURETIC POLYPEPTIDE IN ANAESTHETIZED DOCA-SALT HYPERTENSIVE RATS

Both natriuretic and hypotensive effects of alpha-human atrial natriuretic polypeptide (alpha-hANP) were investigated in anaesthetized DOCA-salt hypertensive rats and control rats. An intravenous injection of two doses (0.3 and 3.0 micrograms/kg body weight) of alpha-hANP produced a rapid and marked increase in natriuresis and fall in blood pressure in DOCA-salt rats. Natriuretic and hypotensive effects of alpha-hANP in DOCA-salt rats were significantly greater than those in the control rats. It is suggested that DOCA-salt rats may have an enhanced natriuretic and hypotensive responsiveness to alpha-hANP.     

COMPARISON OF THE EFFECTS OF OUABAIN AND BRAIN NATRIURETIC PEPTIDE IN SALINE-LOADED SHEEP

1. It has been claimed that ouabain is an endogenous hormone that may be pivotal in the pathogenesis of some forms of hypertension and may exaggerate natriuresis in situations characterized by volume overload. We compared the haemodynamic, renal and endocrine effects of ouabain (at approximately 187 ng/kg per min for 2 h) with those of brain natriuretic peptide (BNP; at 5 pmol/kg per min for 2 h) in nine saline-loaded sheep in a balanced, randomized, single-blind, placebo-controlled crossover study. 2. Brain natriuretic peptide infusion reduced mean arterial pressure whereas ouabain infusion caused no change. Haematocrit rose steadily during BNP infusion but fell during ouabain infusion. Neither ouabain nor BNP affected urine volume, sodium, potassium or creatinine excretion. Mean heart rate declined during the ouabain and placebo infusions, but was not altered during BNP infusion. Endogenous ouabain concentrations were not detectable at baseline or during BNP or placebo infusions, but rose to concentrations of 11 ± 1.3 nmol/L during the ouabain infusion. 3. These results suggest that ouabain is not an endogenous hormone present at physiologically relevant concentrations. Furthermore, ouabain does not cause natriuresis during saline-loading in sheep and is therefore unlikely to be responsible for the exaggerated natriuresis seen in some forms of hypertension.     

CHF患者cAMP cGMP和NE ANF的变化及临床意义

通过放免法和高压液相色谱－电化学法，测定了９２例充血性心力衰竭（ＣＨＦ）患者血浆环核苷酸（ｃＡＭＰ、ｃＧＭＰ）、心钠素（ＡＮＦ）和去甲肾上腺素（ＮＥ）水平。结果表明：血浆ｃＡＭＰ、ｃＧＭＰ和ＡＮＦ、ＮＥ浓度随着心衰程度加重而显著增加，ｃＡＭＰ／ｃＧＭＰ比值下降，与病因无关；心衰纠正后，上述指标明显恢复。血浆ｃＡＭＰ、ｃＧＭＰ与ＮＥ、ＡＮＦ水平显著相关。提示：血浆环核苷酸浓度同ＮＥ、ＡＮＦ一样，可作为评价ＣＨＦ患者心功能和观察疗效的一种生化指标。     

ATRIAL NATRIURETIC HORMONES ORIGINATING FROM THE N-TERMINUS OF THE ATRIAL NATRIURETIC FACTOR PROHORMONE

1. Four peptide hormones consisting of amino acids 1–30 (Long Acting Sodium Stimulator), 31–67 (Vessel Dilator), 79–98 (Kaliuretic Stimulator) and 99–126 (Atrial Natriuretic Factor [ANF]) originate from the same 126 amino acid ANF prohormone. 2. Each of these four peptide hormones circulates as a distinct peptide with vessel dilator and long acting sodium stimulator circulating at 10- to 24-fold higher concentrations than ANF while kaliuretic stimulator circulates at a three-fold higher concentration than ANF. 3. Each of these peptide hormones is released with an increase in central volume causing stretch of the atrium of the heart and with rapid heart beats greater than 125 beats/min. 4. Each of these peptide hormones lowers blood pressure, causes a diuresis and enhances sodium and/or potassium excretion. 5. In disease states which retain sodium and water such as congestive heart failure (CHF), each of these atrial peptides increases in the circulation proportionately to the severity of sodium retention, but of the radioimmunoassays to each of these hormones only the vessel dilator radioimmunoassay differentiates between mild (class I) CHF and healthy individuals.     

EFFECT OF ATRIAL NATRIURETIC PEPTIDE ON CELLULAR ELEMENT CONCENTRATIONS IN RAT PROXIMAL TUBULES: EVIDENCE FOR INHIBITION OF THE SODIUM PUMP

1. In order to further define the action of atrial natriuretic peptide (ANP) on proximal tubular (PT) transport, combined clearance and electron microprobe X-ray (EMPX) experiments were performed on five male Wistar rats infused with ANP (0.16 nmol/kg per h) and nine control animals. 2. Electron microprobe X-ray analysis of PT cell electrolytes (mmol/ kg wet weight) revealed a similar [Na]_i in both the control and ANP treated groups (16.4 ± 0.4 vs 16.5 ± 0.4; P= 0.894). [Cl]_i was lower in the ANP treated animals (14.8 ± 0.3 vs 12.0 ± 0.3; P<0. 0001) as was [K]_i (131.4 ± 1.4 vs 114 ± 1.7; P<0.0001). The PT cells in the ANP treated group had a significant reduction in dry weight (20.1 ± 0.3 g%vs 19.0 ± 0.3 g%; P<0.024), indicating significant cell swelling. Thus, despite a normal [Na]_i, there was net accumulation of Na_i following ANP treatment. 3. These results are consistent with accumulation of Nai due to inhibition of the Na pump followed by cell swelling and subsequent regulatory volume decrease with exit of K and Cl. These results are the first to show the effect of ANP on PT intracellular electrolytes.     

SUPPRESSOR CALCIUM INFUSION RAISES PLASMA ATRIAL NATRIURETIC PEPTIDE CONCENTRATIONS IN HUMANS

1. Calcium was infused in normal subjects in subpressor dosage to examine the effects of raised calcium levels on atrial natriuretic peptide (ANP) concentrations. 2. Calcium infusion progressively raised serum ionized and total calcium concentrations significantly, without raising mean arterial pressure or heart rate. 3. Plasma ANP concentrations increased significantly by 5 min of infusion and increased further by 15 min (approximately 40%) to levels which were maintained to 60 min. 4. Urinary sodium excretion increased by 140% during calcium infusion. 5. Calcium may affect secretory as well as contractile functions of the atrial myocyte.     

NATRIURETIC EFFECT OF CHRONICALLY ADMINISTERED α-HUMAN ATRIAL NATRIURETIC POLYPEPTIDE IN SODIUM DEPLETED OR REPLETED CONSCIOUS SPONTANEOUSLY HYPERTENSIVE RATS

Hypotensive and natriuretic effects of chronically administered alpha-human atrial natriuretic polypeptide (alpha-hANP) were investigated in conscious spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) in both sodium depletion and repletion. Systolic blood pressure was significantly reduced in SHR and WKY in both sodium deplete and replete states. Urinary sodium excretion was significantly increased in SHR and tended to be increased in WKY on sodium repletion, but remained unchanged on sodium depletion. It is suggested that extracellular fluid volume may be an important determinant factor of the natriuretic action of ANP but may not affect the hypotensive effect.     

金丝桃甙镇痛作用的机制

用小鼠光热辐射甩尾模型证明,低钙和高钙分别能增强和拮抗Hyp的镇痛作用。在痛介质诱发传入神经放电的模型上,同样证明低钙或高钙能显著加强或拮抗Hyp对组胺和氯化钾诱发神经放电的抑制作用。促进Ca²⁺内流的A₂₃₁₈₇几乎完全拮抗Hyp的末梢镇痛作用,并且在蛙坐骨神经标本上,Hyp可抑制KCl诱发的Ca²⁺内流。提示Hyp的镇痛作用与减少感觉神经末梢Ca²⁺内流有密切关系。     

EFFECT OF ATRIAL NATRIURETIC PEPTIDE ON COLLECTING DUCT FUNCTION EVALUATED BY STOP-FLOW IN RABBITS

1. The effect of a low dose of a synthetic atrial natriuretic peptide (ANP), rat atriopeptin II (23 amino acids), on stop-flow sodium concentrations was examined in rabbits in water diuresis. 2. Atrial natriuretic peptide (2 micrograms/kg body weight) was injected intravenously as a bolus either before or after the commencement of stop-flow. 3. Atrial natriuretic peptide induced a significant natriuresis within 2 min of injection. This natriuresis was associated with smaller increases in urine volume and potassium excretion. Atrial natriuretic peptide did not alter blood pressure. 4. Atrial natriuretic peptide did not significantly alter stop-flow sodium concentrations. 5. These findings indicate that ANP does not directly alter sodium transport across medullary collecting ducts. 6. It is proposed that ANP acts via a mediator to alter sodium movement across terminal segments of the nephron.     

EFFECTS OF SODIUM DEPLETION ON TISSUE CONCENTRATIONS OF THE NATRIURETIC HORMONE VASOACTIVE INTESTINAL PEPTIDE

1. Variations in dietary sodium intake have been shown to affect the plasma concentration, the metabolic clearance rate and secretion rate of vasoactive intestinal peptide (VIP). In this study we sought to determine the effect of sodium depletion on the concentration of VIP in plasma and in three tissues, namely heart, lung and kidney. 2. Male Sprague-Dawley rats were placed on low or normal sodium diets and drinking water ad libitum. A third group was placed on a low salt diet and in addition were given frusemide, 1 mg/kg per day in the drinking water. After 7 days the rats were killed, a blood sample collected and tissues harvested. VIP concentrations were determined by radio-immunoassay on unextracted plasma and in tissue after extraction. 3. There were significant differences between the three groups in the Concentration of VIP in the lung (P< 0.0005), kidney (P< 0.005) and plasma (P< 0.025) but not the heart. In the group that received frusemide and the low sodium diet, VIP in the lung was significantly lower than the low sodium (P< 0.005) and normal sodium (P< 0.0001) groups. Similar differences were noted in the kidney (frusemide vs low sodium, P< 0.001; frusemide vs normal, P< 0.01) and plasma (frusemide vs low sodium P< 0.001, frusemide vs normal P< 0.05). 4. We conclude that sodium depletion decreases the concentration of VIP in plasma and in its metabolizing tissues.     

RENAL EFFECTS OF ATRIAL NATRIURETIC FACTOR (99–126) IN CONSCIOUS SODIUM-REPLETE SHEEP

1. The effect of renal arterial infusion of synthetic human atrial natriuretic factor (ANF (99-126] on renal function in the conscious euvolaemic sheep was characterized. ANF (99-126) was infused for 2 h at 5 and 50 micrograms/h into the renal artery of crossbred Merino ewes with chronically indwelling cannulae inserted in the renal artery. The effect on absolute and fractional excretion of Na, K, Ca, Cl and HCO3, glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and free water clearance (CH2O) were measured. 2. Infusion at 50 micrograms/h produced a fourfold increase in Na and Cl excretion. Ca excretion increased eightfold, while K and HCO3 increased by small amounts. At the lower dose only Na, Cl and Ca excretion increased significantly. The changes in absolute excretion of each ion were closely mirrored by changes in fractional excretion. CH2O became more negative at both levels of infusion. Small changes in GFR were measured at both rates of infusion. No changes in ERPF or renin secretion were observed. 3. ANF (99-126) infusion at 50 micrograms/h for 1 h increased the excretion of Li, such that more than 70% of the change in Na excretion was associated with the changes in Li clearance. Changes in GFR accounted for less than 10% of change in Na excretion. 4. Following either long-term (50 micrograms/h for 6 h) or repeated short-term (20 micrograms/h for 30 min) infusions of ANF (99-126), the response of Na excretion was not sustained. The mechanisms of the tachyphylaxis remains undetermined. 5. ANF (99-126) is a powerful stimulus to the absolute and fractional excretion of Na, K, Ca, Cl and HCO3. The mechanism of action is not known, but appears to be related to changes in tubular function and/or a change in glomerulotubular balance.     

CAPTOPRIL ANTAGONIZES THE HYPOTENSIVE ACTION OF ATRIAL NATRIURETIC PEPTIDE IN THE ANAESTHETIZED RAT

Atrial natriuretic peptide (8-33; ANP) caused a prolonged hypotensive response following intravenous injection in anaesthetized rats. This response was abolished by captopril treatment and restored by concomitant angiotensin II infusion. These results suggest that ANP exerts its hypotensive action in the anaesthetized rat by the antagonism of the vasoconstrictor action of endogenous angiotensin II.     

RENAL EFFECTS OF ATRIAL NATRIURETIC FACTOR (99–126) IN WATER-DEPRIVED SHEEP

1. The renal response to renal arterial infusion of synthetic human atrial natriuretic factor (ANF) (99-126) at 50 micrograms/h was examined in conscious sheep dehydrated by 48 h water deprivation and was compared with the response of normally hydrated animals. 2. Renal arterial infusion of ANF produced increases in the excretion of Na, K, Ca and urine in both dehydrated and normally hydrated animals, although the effect was significantly blunted in dehydrated animals compared with normally hydrated animals. 3. The attenuation of renal effects of ANF in dehydrated animals is probably due to the negative sodium and/or fluid balance of the dehydrated animals.     

Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’: REGULATION OF RENAL TUBULAR SODIUM TRANSPORT BY ANGIOTENSIN II AND ATRIAL NATRIURETIC FACTOR

• 1 The effects of angiotensin II (AngII) on water and electrolyte transport are biphasic and dose-dependent, such that low concentrations (10^?12 to 10^?9 mol/L) stimulate reabsorption and high concentrations (10^?7 to 10^?6 mol/L) inhibit reabsorption. Similar dose-response relationships have been obtained for luminal and peritubular addition of AngII.
• 2 The cellular responses to AngII are mediated via AT₁ receptors coupled via G-regulatory proteins to several possible signal transduction pathways. These include the inhibition of adenylyl cyclase, activation of phospholipases A₂, C or D and Ca²⁺ release in response to inositol-1,4,5,-triphosphate or following Ca²⁺ channel opening induced by the arachidonic acid metabolite 5,6,-epoxy-eicosatrienoic acid. In the brush border membrane, transduction of the AngII signal involves phospholipase A₂, but does not require second messengers.
• 3 Angiotensin II affects transepithelial sodium transport by modulation of Na⁺/H⁺ exchange at the luminal membrane and Na⁺/HCO₃ cotransport, Na⁺/K⁺-ATPase activity and K⁺ conductance at the basolateral membrane.
• 4 Atrial natriuretic factor (ANF) does not appear to affect proximal tubular sodium transport directly, but acts via specific receptors on the basolateral and brush border membranes to raise intracellular cGMP levels and inhibit AngII-stimulated transport.
• 5 It is concluded that there is a receptor-mediated action of ANF on proximal tubule reabsorption acting via elevation of cGMP to inhibit AngII-stimulated sodium transport. This effect is exerted by peptides delivered at both luminal and peritubular sides of the epithelium and provides a basis for the modulation by ANF of proximal glomerulotubular balance. The evidence reviewed supports the concept that in the proximal tubule, AngII and ANF act antagonistically in their roles as regulators of extracellular fluid volume.

     

BLUNTED NATRIURETIC RESPONSE TO ENDOGENOUS ATRIAL NATRIURETIC PEPTIDE DURING RAPID CARDIAC PACING IN ANAESTHETIZED DOGS

1. We investigated whether diuresis and natriuresis induced by endogenous atrial natriuretic peptide (ANP) were blunted during rapid cardiac pacing. 2. Changes in plasma ANP, renal function and haemody-namics during rapid cardiac pacing were studied in anaesthetized closed-chest dogs. Dogs were paced via the right ventricle at a rate of 200 b.p.m. (moderate pacing) or 250 b.p.m. (severe pacing) for 180 min. 3. The maximal increases in plasma ANP and urinary excretion of cGMP during severe pacing were four- and three-fold higher, respectively, than those during moderate pacing. Despite the higher concentration of plasma ANP, the maximal increases in urine volume, urinary excretion of sodium and fractional excretion of sodium during severe pacing were similar to those during moderate pacing. Mean arterial pressure and renal vascular resistance were decreased only by severe pacing. The increase in total peripheral resistance during severe pacing was significantly smaller than that during moderate pacing. However, the glomerular filtration rate was kept at basal levels by both moderate and severe pacing. 4. These results suggest that there are certain mechanisms that counteract renal tubular sodium reabsorption induced by endogenous ANP under conditions of severe pacing. The suppression occurs at tubular sites but not at glomerular sites. One of the possibilities for the suppression is the decrease in renal perfusion pressure accompanied by decreases in peritubular capillary hydrostatic pressure.     

ROLE OF ATRIAL NATRIURETIC PEPTIDE IN LONG-TERM VOLUME HOMEOSTASIS

1. Long-term volume homeostasis is linked very closely to long-term arterial pressure control through the renal-body fluid feedback mechanism. A key feature of this control system is the ability of the kidneys to respond to changes in arterial pressure by altering renal excretion of salt and water, often referred to as renal-pressure natriuresis. 2. Quantitative studies indicate that ANP secretion is relatively sensitive to changes in atrial pressure and that the rate of hormonal secretion does not adapt to continuous long-term stimulation. 3. Under normal conditions, the renal-body fluid feedback mechanism for arterial pressure control is very efficient in minimizing changes in body fluid volumes during alterations in sodium intake. Therefore, only small changes in atrial pressure and ANP secretion occur. Alterations in plasma ANP concentration within physiological levels have little effect on renal-pressure natriuresis and, therefore, have little impact on volume homeostasis. 4. When the renal-body fluid feedback mechanism for arterial pressure control is impaired and body fluid volumes are elevated, such as in heart failure, large increases in atrial pressure and ANP secretion occur. The resultant pathophysiological plasma levels of ANP exert sustained natriuretic effects and chronically shift renal-pressure natriuresis to lower arterial pressures. In the absence of this chronic effect of ANP on renal-pressure natriuresis, reduced arterial pressure in compensated heart failure would result in protracted retention of salt and water and additional increments in body fluid volumes.     

ATRIAL NATRIURETIC FACTOR IN CHRONIC RENAL FAILURE: STUDIES IN MAN AND THE RAT

1. Plasma concentration and atrial content of atrial natriuretic factor (ANF) were measured in rats with chronic renal failure induced by subtotal nephrectomy. 2. Plasma ANF was higher, and atrial ANF content lower in rats with renal failure when compared with sham-operated controls. 3. Plasma renin activity (PRA) and ANF were elevated at 1 week following subtotal nephrectomy. After 1 month plasma ANF had risen further, but PRA was suppressed to below control values. 4. Plasma ANF was also measured in six patients with chronic renal failure undergoing routine haemodialysis. 5. Elevated plasma ANF levels in patients with renal failure were lowered by haemodialysis, although extraction of ANF across the dialysis membrane was negligible. 6. Secretion of ANF is increased in chronic renal failure in man and the rat, possibly mediated by increased intravascular volume.